Cell therapy for cardiovascular disease

Jonathan R Murrow; Saurabh S. Dhawan; Arshed A. Quyyumi

doi:10.1007/978-1-84882-637-3_8

Cell therapy for cardiovascular disease

Jonathan R Murrow, Saurabh S. Dhawan, Arshed A. Quyyumi

Research output: Chapter in Book/Report/Conference proceeding › Chapter

1 Scopus citations

Abstract

Advances in diagnosis and treatment have dramatically impacted morbidity and mortality from cardiovascular disease over the past several decades. ¹ The discovery in 1960 of stem cells capable of regeneration and repair sparked interest in a new mode of therapy for heart disease beyond pharmaceuticals and cardiac devices.² Over the past 10 years, work has focused on five key cell types - the endothelial mononuclear progenitor cell, the autologous skeletal myoblast, the allogeneic mesenchymal stem cell, the resident cardiac stem cell, and the human embryonic stem cell - as potential therapeutic agents, which may further contribute to gains in treating cardiovascular disease. This chapter aims to review these cell types, their preclinical underpinnings, the nascent clinical studies, and limitations observed in their use.

Original language	English (US)
Title of host publication	Advances in Vascular Medicine
Publisher	Springer
Pages	131-151
Number of pages	21
ISBN (Print)	9781848826366
DOIs	https://doi.org/10.1007/978-1-84882-637-3_8
State	Published - Dec 1 2010
Externally published	Yes

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1007/978-1-84882-637-3_8

Fingerprint Dive into the research topics of 'Cell therapy for cardiovascular disease'. Together they form a unique fingerprint.

Cite this

Murrow, J. R., Dhawan, S. S., & Quyyumi, A. A. (2010). Cell therapy for cardiovascular disease. In Advances in Vascular Medicine (pp. 131-151). Springer. https://doi.org/10.1007/978-1-84882-637-3_8

@inbook{20ca24e4e0d54cf09da84eb083b9f415,

title = "Cell therapy for cardiovascular disease",

abstract = "Advances in diagnosis and treatment have dramatically impacted morbidity and mortality from cardiovascular disease over the past several decades. 1 The discovery in 1960 of stem cells capable of regeneration and repair sparked interest in a new mode of therapy for heart disease beyond pharmaceuticals and cardiac devices.2 Over the past 10 years, work has focused on five key cell types - the endothelial mononuclear progenitor cell, the autologous skeletal myoblast, the allogeneic mesenchymal stem cell, the resident cardiac stem cell, and the human embryonic stem cell - as potential therapeutic agents, which may further contribute to gains in treating cardiovascular disease. This chapter aims to review these cell types, their preclinical underpinnings, the nascent clinical studies, and limitations observed in their use.",

author = "Murrow, {Jonathan R} and Dhawan, {Saurabh S.} and Quyyumi, {Arshed A.}",

year = "2010",

month = dec,

day = "1",

doi = "10.1007/978-1-84882-637-3_8",

language = "English (US)",

isbn = "9781848826366",

pages = "131--151",

booktitle = "Advances in Vascular Medicine",

publisher = "Springer",

}

TY - CHAP

T1 - Cell therapy for cardiovascular disease

AU - Murrow, Jonathan R

AU - Dhawan, Saurabh S.

AU - Quyyumi, Arshed A.

PY - 2010/12/1

Y1 - 2010/12/1

N2 - Advances in diagnosis and treatment have dramatically impacted morbidity and mortality from cardiovascular disease over the past several decades. 1 The discovery in 1960 of stem cells capable of regeneration and repair sparked interest in a new mode of therapy for heart disease beyond pharmaceuticals and cardiac devices.2 Over the past 10 years, work has focused on five key cell types - the endothelial mononuclear progenitor cell, the autologous skeletal myoblast, the allogeneic mesenchymal stem cell, the resident cardiac stem cell, and the human embryonic stem cell - as potential therapeutic agents, which may further contribute to gains in treating cardiovascular disease. This chapter aims to review these cell types, their preclinical underpinnings, the nascent clinical studies, and limitations observed in their use.

AB - Advances in diagnosis and treatment have dramatically impacted morbidity and mortality from cardiovascular disease over the past several decades. 1 The discovery in 1960 of stem cells capable of regeneration and repair sparked interest in a new mode of therapy for heart disease beyond pharmaceuticals and cardiac devices.2 Over the past 10 years, work has focused on five key cell types - the endothelial mononuclear progenitor cell, the autologous skeletal myoblast, the allogeneic mesenchymal stem cell, the resident cardiac stem cell, and the human embryonic stem cell - as potential therapeutic agents, which may further contribute to gains in treating cardiovascular disease. This chapter aims to review these cell types, their preclinical underpinnings, the nascent clinical studies, and limitations observed in their use.

UR - http://www.scopus.com/inward/record.url?scp=84892106608&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892106608&partnerID=8YFLogxK

U2 - 10.1007/978-1-84882-637-3_8

DO - 10.1007/978-1-84882-637-3_8

M3 - Chapter

AN - SCOPUS:84892106608

SN - 9781848826366

SP - 131

EP - 151

BT - Advances in Vascular Medicine

PB - Springer

ER -